We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Expression Analysis Expands Affymetrix Capabilities

Want a FREE PDF version of this news story?

Complete the form below and we will email you a PDF version of "Expression Analysis Expands Affymetrix Capabilities "

Listen with
Register for FREE to listen to this article
Thank you. Listen to this article using the player above.
Read time:

Expression Analysis has concluded an upgrade of their laboratory systems to support the latest in Affymetrix high-content and specialty products.

“We've now completed the upgrade of our infrastructure to include the new Affymetrix 7G and MegAllele scanners, allowing us to process the newly released Affymetrix GeneChip® Exon Arrays, the Affymetrix GeneChip 500K Mapping Array Set and the MegAllele DME-T assay developed by ParAllele,” said Dr. Tom Goralski, Expression Analysis' Laboratory Director.

“These advancements give investigators additional tools to further enhance their genomic research and development efforts,” said Goralski.

The Affymetrix 7G GeneChip Scanner 3000 is designed to support the analysis of microarrays capable of providing up to 500% more data than previous versions.

The 500K Mapping Array Set enhances the ability to support high density genotyping studies on a significantly reduced "cost per SNP" basis.

The Exon Array provides researchers with exon-level expression profiling, allowing for the interrogation of over one million individual exons and splice variants across the entire human genome.

“The upgrades to our instruments and our Laboratory Information Management System were necessary to keep pace with advancements in genomic research,” said Steve Casey, Expression Analysis' founder and Chief Operating Officer.

“As the first microarray services company to obtain GLP compliance and CLIA registration, we are always looking to the future, to ensure we are ready and capable to support our clients' research requirements,” said Casey.

“We're proud to be able to once again take the lead in providing the scientific community access to the latest and best genomic technologies available.”